Wedbush restated their outperform rating on shares of Y-mAbs Therapeutics (NASDAQ:YMAB – Free Report) in a research report released on Tuesday, Marketbeat Ratings reports. They currently have a $23.00 target price on the stock.
Other equities analysts have also recently issued research reports about the stock. Cantor Fitzgerald reaffirmed an overweight rating and set a $20.00 price target on shares of Y-mAbs Therapeutics in a research report on Monday. BMO Capital Markets decreased their target price on Y-mAbs Therapeutics from $26.00 to $25.00 and set an outperform rating for the company in a research report on Tuesday, August 13th. HC Wainwright reissued a buy rating and set a $22.00 price target on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. Morgan Stanley decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an underweight rating for the company in a report on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a buy rating and set a $26.00 target price on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of Moderate Buy and a consensus target price of $21.14.
Get Our Latest Stock Report on Y-mAbs Therapeutics
Y-mAbs Therapeutics Stock Performance
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million for the quarter, compared to analysts’ expectations of $23.09 million. During the same quarter in the prior year, the firm earned ($0.14) earnings per share. As a group, research analysts predict that Y-mAbs Therapeutics will post -0.57 EPS for the current year.
Insiders Place Their Bets
In other Y-mAbs Therapeutics news, COO Joris Wilms sold 5,000 shares of the business’s stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 21.50% of the stock is owned by corporate insiders.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the business. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth approximately $562,000. Squarepoint Ops LLC lifted its position in Y-mAbs Therapeutics by 143.4% in the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after purchasing an additional 74,452 shares during the period. Millennium Management LLC boosted its stake in Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Dimensional Fund Advisors LP increased its position in shares of Y-mAbs Therapeutics by 15.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock valued at $5,853,000 after purchasing an additional 65,732 shares during the period. Finally, Boston Partners bought a new stake in shares of Y-mAbs Therapeutics in the 1st quarter worth $556,000. Institutional investors and hedge funds own 70.85% of the company’s stock.
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
See Also
- Five stocks we like better than Y-mAbs Therapeutics
- Utilities Stocks Explained – How and Why to Invest in Utilities
- 3 Leveraged ETFs to Multiply Returns
- What Are Dividend Achievers? An Introduction
- A Tale of Two Titans: Unveiling the Value in Baidu and JD.com
- What Is WallStreetBets and What Stocks Are They Targeting?
- Is the AI-Capable iPhone 16 the Start of a Sales Super-Cycle?
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.